Chipscreen Biosciences (688321.SH): CS43158 Tablets Receives Drug Clinical Trial Approval Notice

Zhitong Finance APP News, Chipscreen Biosciences (688321.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, agreeing to the company's product CS43158 tablets to conduct clinical trials for acute myeloid leukemia. CS43158 is a multi-target protein kinase inhibitor that can simultaneously cover the driving oncogenic pathways and bypass activation resistance pathways of acute myeloid leukemia (AML), with the dual effect of targeting primary driving mutations and overcoming secondary resistance.